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Abstract Surgical myectomy and ethanol ablation are
established intervention strategies for left ventricular outflow
obstruction in hypertrophic cardiomyopathy. Safety and effi-
cacy limitations of these interventions call for a minimally
invasive, potentially safer, and more efficacious strategy. In
this study, we aimed to evaluate the feasibility of
echocardiography-guided percutaneous per-ventricular laser
ablation of a ventricular septum in a canine model. Six domes-
tic dogs were chosen for the study. A 21G needle was inserted
into the right ventricle with its tip reaching the targeted basal
to mid-septum, after which laser ablation was performed as
follows: 1-W laser for 3 min (180 J) at the basal segment and
5 min (300 J) at middle segment of the septum, respectively.
Echocardiography, blood chemistry tests, and pathology ex-
amination were performed to assess the results of laser abla-
tion. No death or major complications, i.e., tamponade, peri-
cardial effusion, or ventricular fibrillation, occurred. The
laser-ablated areas were well demarcated in the results of the
pathological examination. The diameters of the ablated re-
gions were 4.42±0.57 and 5.28±0.83 mm for 3 and 5 min
ablation, respectively. Pre-ablation and post-ablation, cardiac
enzymes were found to increase significantly while no
significant differences were found among M-mode, 2D
(LVEF), pulsed-wave (PW) Doppler, and tissue Doppler im-
aging (TDI) measurements. Contrast echocardiography con-
firmed the perfusion defects in the ablated regions. Micro-
scopically, the ablated myocardium showed coagulative
changes and a sparse distribution of disappearing nuclei and
an increase in eosinophil number were observed. Our study
suggests that percutaneous and per-ventricular laser ablation
of the septum is feasible, potentially safe and efficacious, and
warrants further investigation and validation.
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Introduction
Hypertrophic cardiomyopathy (HCM) is an autosomal domi-
nant disease of the cardiac sarcomere with an occurrence of
1:500 worldwide [1]. HCM mainly manifests as left ventricu-
lar (LV) hypertrophy (≥15 mm) [2] and left ventricular out-
flow tract (LVOT) obstruction (accounting for up to 70 % of
patients) [3], thereby leading to heart failure with dyspnea,
chest pain, atrial fibrillation, and sudden death. Thus, most
treatment strategies are directed at enlarging the LVOT and
relieving the LVOT obstruction. Conservative medications
(β-blockers, calcium-channel blockers, and anti-arrhythmic
agents) are used to treat the vast majority of patients. Invasive
therapy, which includes surgical myectomy, septal ethanol
ablation, and dual-chamber pacing is introduced to patients
with refractory symptoms or drug resistance. Surgical septal
myectomy generally involves resection of hypertrophic tissue
from the basal septum and has been advocated as the gold
standard for symptomatic patients with severe complications
[4]. Ethanol ablation is a less invasive approach that is per-
formed by chemically inducing myocardial infarction and is
an effective method for reducing septal thickness and
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relieving LVOT pressure gradients [5]. Studies have shown
that both treatments improve functional status with similar
HCM-related mortality [6], but no randomized trials compar-
ing the two procedures have been performed [7]. Note that
postoperative complications of left bundle branch block and
right bundle branch block were found, and the occurrence
rates were up to 46 and 40 % for surgical myectomy and
ethanol ablation, respectively [8]. Considering the sternotomy
and relatively high patients’ tolerance required in myectomy,
the potentially risky misplacement of ethanol and the anatom-
ic variability of the vascularized hypertrophic septum, and the
potential risk of conduction block after these two treatments,
the development of new minimally invasive approach is
warranted.
Transcatheter intervention therapies, which include radio
frequency (RF), microwave (WMA), laser, and cryoablation,
have been extensively studied for the treatment of cardiac
diseases, such as atrial fibrillation [9], ventricular tachycardia
[10, 11], and pulmonary atresia [12]. Regarding septal abla-
tion, the advantages of transcatheter RF ablation over ethanol
ablation and myectomy include high accuracy and low risk of
damaging the conduction system [13]. The mechanism of RF
septal ablation to reduce LVOT gradient is by hypokinesis or
akinesis of the ablated region [14], rather than thinning the
septum in surgical septal myectomy [4]. High-intensity fo-
cused ultrasound (HIFU) was reported to be efficacious in
ablating the septum and the LV free wall in canine myocardi-
um without influencing the cardiac function [15]. However,
given the difficulty in controlling the HIFU energy, the trans-
ducer size and the pulmonary vein isolation hamper the appli-
cation of this technique. Laser has a primary advantage in
magnetic resonance imaging (MRI) compatibility because it
can be coupled with optical fiber [16]. It shows less efficiency
in ablation compared with RF andWMA because of its scatter
and rapid absorption by tissues [17]. However, this makes the
progression of laser ablation more controllable as a precise
and efficient light source for ablation.
From the mentioned studies, refinement in ablation tech-
nology facilitates the widespread application of this technique.
Most minimal invasive ablation systems use a transcatheter
during operation. Complications of transcatheter ablation, in-
cluding thromboembolism, pulmonary vein stenosis [18],
stroke, cardiac tamponade, and esophageal perforations, may
occur [19]. Moreover, a long period of radiation exposure is
unavoidable for both operator and patient during the transcath-
eter procedure. Thus, we aimed to investigate a potentially
safer and more efficacious strategy for septum ablation. Min-
imal invasive percutaneous ablation has been widely used on
focal benign gynecologic tumors [20] and on hepatic, renal,
and lung malignancies [21, 22]. To date, few studies have
been reported on percutaneous cardiac ablation without the
use of a catheter. The occurrence of severe complications,
such as pericardial tamponade, pericardial effusion, or
ventricular fibrillation during the operation, is unclear. The
variation in global and regional cardiac function during and
after ablation also remains unknown.
The aim of this paper is to validate the feasibility of
echocardiography-guided percutaneous per-ventricular laser
ablation of the canine ventricular septum. An in vivo experi-
ment was performed by using a laser inserted from the apical
region on the right ventricle (RV) side to the targeted septum
under the guidance of echocardiography. Echocardiography,
blood chemistry tests, and pathology examination were per-
formed to assess the results of laser ablation.
Materials and methods
Animal preparation
All animal experiments were approved by the local animal
ethical committee for research animal care and performed in
accordance with the ethical standards of the Declaration of
Helsinki. Six domestic dogs, weighing 13±2 kg, were anes-
thetizedwith an intravascular injection of 1.5 ml (0.1ml/kg, as
required) xylazine hydrochloride (Hua Mu Animal Care Inc.,
Ji Lin, China), followed by 0.75 ml of the same drug to main-
tain anesthesia. The hair around the heart region was removed
before the operation. Intravascular injection of saline was giv-
en during the operation.
Echocardiography-guided percutaneous laser ablation
of in vivo canine ventricular septum
Neodymium-yttrium-aluminum-garnet laser (Nd:YAG, 800–
1064 nm wavelength, 300-μm-diameter fiber, Echo Laser
X4, Elesta S.R.L., Italy) was connected to an ultrasound
scanner (MyLab 9.0, Esaote, Italy) for laser ablation, under
the guidance of another ultrasound scanner (Acuson Sequoia
512, Siemens, Germany) with a transducer 4V1-C. In view
of LV long axis, a needle (21G, PTC, ECOCHIBA, Italy)
was injected into the RV obliquely from the apical area via
percutaneous route, as shown in the diagram of Fig. 1a. The
angle of insertion against the septum α in Fig. 1a was ap-
proximately less than 45°. The tip of the needle was inserted
into the target septum along the guideline shown Fig. 1b.
Note that the papillary muscle and chordae tendineae in RV
were avoided under the guidance of the ultrasound during the
insertion. Then, the laser fiber was inserted through the nee-
dle, and its contact with the septum was maintained. Each
dog received two ablations. The first ablation was located at
the basal segment of ventricular septum (avoiding the mem-
branous segment) using a 1-W laser for 3 min (180 J). The
second ablation was located at the middle segment using a 1-
W laser for 5 min (300 J). Heart rate and blood pressure were
recorded before and after the ablation.
646 Lasers Med Sci (2016) 31:645–651
Echocardiographic evaluation
Two-dimensional echocardiography was acquired before ab-
lation and immediately after ablation by applying an ultra-
sound scanner (iE33, Philips, The Netherlands) and transducer
S5-1 (frequency: 1–5 MHz) to evaluate the variation in cardi-
ac function. The measured echocardiographic parameters in-
cluded the following: ejection fraction (EF), motion of the
regional septum (at basal, middle, and apical segment) and
posterior wall (basal, middle, and apical segments) in M-
mode, ratio of peak early mitral inflow velocity (E-wave)
and peak late mitral inflow velocity (A-wave) (E/A) in the
pulsed-wave (PW) Doppler, E′/A′, measured at the mitral
valve (MV) annulus, the peak systolic (Sa) and diastolic
waves (Ea and Aa) in the velocity spectrum of tissue Doppler
imaging (TDI) at the ablated area, and pressure gradient in
LVOT. Each dataset was measured from three cardiac cycles.
Serology examination
Blood (5 ml) was intravenously drawn from each dog before
ablation and 3 hours after ablation. The cardiac enzymes, in-
cluding aspartic acid transaminase (AST), lactate dehydroge-
nase (LDH), creatine kinase (CK), and creatine kinase isoform
(CK-MB), were examined.
Gross and pathological examinations
All dogs were sacrificed after collecting blood samples, and
the hearts were removed for the gross and pathological exam-
inations. Each heart was dissected to approximately 1-mm-
thick slices to expose and carefully ascertain the range of
ablation lesions. Maximal lesion length (D1), width (D2),
and depth (D3) were measured, and the mean diameters
(D1+D2+D3)/3 and mean volumes (0.5233 D1D2D3) [15]
were calculated. Then, the ablated cardiac specimens were
fixed in 10 % phosphate-buffered formalin (pH 7) and sent
for histopathological examinations.
Statistics
The results were presented as mean± standard deviation. A
paired T test (two-tailed) was performed usingMATLAB soft-
ware (MATLAB 2010a, The MathWorks Inc., Natick, MA,
USA). The significance level was set at 0.05, and P values less
than 0.05 indicated a statistically significant difference.
Results
All dogs survived during and after the process of ablation
without major physiological complications (e.g., pericardial
tamponade, pericardial effusion, and ventricular fibrillation).
No damage to papillary muscle and chordae tendineae in RV
was found. Before and after ablation, the heart rates (91.7
±16.1 vs. 81.1±29.6 bpm; P>0.05) and blood systolic pres-
sures (112.8±8.1 vs. 116.4±7.3 mmHg; P>0.05) showed no
significant difference.
B-mode and contrast evaluation
The B-mode image in Fig. 2a shows the ablated regions in LV
short-axis view. The hyper-echogenic area (arrow) is the ab-
lated tissue appearing thicker than the surrounding tissues. In
contrast mode (Fig. 2b), perfusion of the ultrasound contrast
agents fills the LVand RV, thereby delineating the septum and
posterior wall. No blood flow is found in the ablated region
(yellow arrow) of the septum.
Echocardiographic evaluation
In Figs. 3 and 4, no significant differences are found in the
global and regional systolic and diastolic functions before and
after the ablation. Factors including EF (Fig. 3a), E/A ratio
(Fig. 3b), E′/A′ ratio (Fig. 3c), pressure gradient of LVOT
(Fig. 3d), amplitude of septal movement (Fig. 4a) and posterior
Fig. 1 aDiagram of the needle path and ablation area ((http://medmovie.
com/library_id/7556/) is acknowledged), b B-mode ultrasound image
showing the needle path in parasternal LV long-axis view, LV left
ventricle, RV right ventricle. The angle α of insertion against the septum
in Fig. 1a maintains less than 45° in the process of the insertion and
ablation
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wall (Fig. 4b) in M-mode, TDI velocity (Sa) (Fig. 4c), and Ea/
Aa ratio at the ablated zone (Fig. 4d) are assessed.
Serologic changes
In Fig. 5a, cardiac enzymes (AST, CK-MB, and CK) signifi-
cantly increase due to ablation of the myocardial cells. No
significant increase in LDH is found before and after ablation.
LDH is generally elevated on the second day after acute myo-
cardial infarction and peaks on the fourth day [23]. Thus,
serum test after 3 hours may be too short to detect the eleva-
tion in LDH.
Gross and pathological examinations
The mean diameter and volume after 5 min ablation are sig-
nificantly larger than the region ablated for 3 min in Fig. 5b.
Figure 5c shows an example of myocardial lesions ablated for
5 min. The charred and coagulated necrotic regions are clearly
seen with borders that distinguished these regions from the
surrounding normal healthy myocardial tissue. A representa-
tive pathological examination of ablated myocardial lesion at
×200 magnification is shown in Fig. 5d. Normal myocytes are
distributed evenly (arrow head) with the nuclei showing small
dark-blue or purple precipitate. The ablated myocardial tissue
(arrow head) is contracted, and the cells close to the laser show
abnormal morphological characteristics. A zone of vacuoles
forms a clear boundary between the ablated and normal tis-
sues, and red blood cells infiltrate the widened intercellular
space. Compared to normal tissue, the ultrastructure of the
lesion is damaged and sparsely distributes, with fewer nuclei
and an increasing number of eosinophils.
Discussion
The effectiveness of the echocardiography-guided laser
ablation of the septum
Laser ablation of the septum is a feasible process, and no
major physiological reactions or complications such as peri-
cardial tamponade, pericardial effusion, and ventricular fibril-
lation were observed during and after ablation. Global and
regional cardiac functions from echocardiographic parameters
did not vary significantly before and after ablation. The basal
segment of the septum presented a decreasing trend in ampli-
tude of movement in M-mode pre-ablation compared with
post-ablation, whereas the amplitude of movement of the three
segments of posterior wall showed an increasing trend in M-
mode. The increasing trend in amplitude of movement of the
posterior wall indicated the compensatory action that main-
tained the systolic function. This observation agreed with the
results obtained from the regional TDI hypokinesis of the
ablated region without significant variation in global cardiac
Fig. 2 a A two-dimensional image showing the position of ablation
(arrows) on the ventricular septum in LV short-axis view. Hyper-echo
region indicates the ablated region. b Contrast mode in parasternal LV
long-axis view, LV left ventricle, RV right ventricle, IVS interventional

























































































Fig. 3 Variation in global systolic and diastolic functions pre- and post-
ablation: a EF, b E/A ratio, c E′/A′ ratio at the MV annulus, d pressure
gradient at LVOT
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function [15]. Decreasing diastolic function (both global pa-
rameters of E/A, E′/A′, and regional parameter of Ea/Aa) was
found post-ablation compared with pre-ablation. A decrease
in diastolic function is known to be a sensitive indicator of
cardiac dysfunction. This trend was possibly due to impaired
myocardial relaxation which resulted in a decrease in the fill-
ing reliance [24].
The results of pathology and the increase of myocardial
enzymes indicated damage to the myocardium. Tissue necro-
sis was clearly observed and suggested irreversible
denaturation of proteins mainly due to thermal injury [25].
Around the ablation crater, visible whitening of irradiated tis-
sue was observed, thereby indicating thermal coagulation as
shown in Fig. 5c [26]. The pathological figure in Fig. 5d
showed a zone of vacuoles lying beneath fragments of carbon
in all lesions. Compared with other thermal ablation ap-
proaches, the laser required a longer time to create lesions.
For example, the insonation time lasted a few seconds when
HIFU ablation was performed at an output power of 2000–




































































































































































Fig. 4 Variation in regional
systolic and diastolic parameters
pre- and post-ablation: a
amplitude of movement of the
basal, middle, and apical
segments of the septum in
M-mode; b amplitude of the
movement of the basal, middle,
and apical segments of the
posterior wall in M-mode; c the
peak systolic wave (Sa) in TDI at
the ablated area; d Ea/Aa ratio at
the ablated area
Fig. 5 a The variation in cardiac
enzyme before and after laser
ablation (*P< 0.05, **P< 0.01);
b the measured mean diameter
and volume of the lesions; c
example of the ablation zone, the
center black region was charred
and surrounded by white
coagulated regions; and d
pathological examinations of
lesions showing the comparison
of the ablated regions and the
normal myocardial tissue.
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(wavelength 454–514 nm, power 2–2.2 W, exposure time 12–
20 min, total energy 1440–2640 J) was reported, and the in
vivo ablated region [27] was comparable with that observed in
this study. In our study, the 1-W power Nd:YAG laser
achieved the desired ablated region in a relatively short time
(3–5 min) with a low intraoperative stimulus. The thickness of
the canine septumwas approximately 6 mm. Low-power laser
instead of high power was utilized to obtain a controllable
lesion size without rapid perforation [28]. The large charred
region caused by high-power laser was expected to reduce the
depth of laser penetration and caused possible damage to the
optical fiber [29]. Hence, considering operational safety, the
laser in this study was shown to be a safe method for in situ
cardiac thermal ablation.
Selection of the insertion path
The needle was inserted into the septum from the apical region
on the RV side in this study. This was due to the lower pres-
sure and slower blood flow in this area than from the LV route
minimizing the occurrence of cardiac tamponade. Caution
must be taken when controlling the insertion angle and depth
of insertion. The needle was inserted obliquely along the sep-
tum because of the anatomical limitations of the canine chest
and to reduce the risk of interventricular septum defect. Verti-
cal insertion should be carefully avoided to minimize the in-
fluence ofmovement caused by respiration. A distance of 1.5–
2 mm from the needle tip to the distal end of the septum on the
LV side in the B-mode image would be appropriate.
Limitation and prospects
This study focused on the short-term response of
echocardiography-guided percutaneous laser ablation of
healthy canine ventricular septum. Future work includes the
long-term observation of safety of this approach on an animal
model with hypertrophic myocardium and investigation of the
underlying mechanism of septum reduction. Furthermore, no
significant variation in cardiac function was found based on
conventional echocardiographic parameters. Other sensitive
parameters like strain may be applied to monitor the influence
of laser ablation on the myocardium in animals of a larger
scale. The standard deviation values in the echocardiographic
results were relatively large because the incident angle of the
needle was not completely identical for each animal. Under
the guidance of echocardiography, we tried to insert the needle
in the position that was closest to the initially targeted region.
The integrity of the canine chest was well preserved, and the
anatomy of the canine heart and the movement caused by
respiration limited the reproducibility of needle insertion to
some extent.
Conclusion
This study investigated the feasibility of the echocardiography-
guided percutaneous per-ventricular laser ablation on intraven-
tricular septum of healthy canine. Nomajor complications, such
as pericardial tamponade, pericardial effusion, and ventricular
fibrillation, occurred during and after ablation. Both patholog-
ical and serological results showed that using a 1-W laser for 3
and 5 min allowed the creation of lesions with effective coag-
ulation and cardiac damage. Real-time echocardiography mon-
itoring presented no significant variation in cardiac function
during and after laser ablation. In summary, percutaneous and
per-ventricular laser ablation of the septum is feasible, poten-
tially safe and efficacious, and may become a viable alternative
and a non-sternotomy solution to septum ablation. Long-term
observation on the experimental outcomes in animals of HCM
model warrants further investigation and validation.
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